India Innovates New Antibiotics to Tackle Drug-Resistant Superbugs

India is grappling with an escalating crisis of drug-resistant infections, particularly within its healthcare settings. Recent reports from The Lancet indicate that antibiotic-resistant superbugs resulted in 1.14 million fatalities globally in 2021 alone. Within India, the toll has been dire; antibiotic-resistant infections claimed around 300,000 lives in 2019 and are responsible for nearly 60,000 newborn deaths each year. The problem predominantly thrives in critical care units where many patients experience severe infections. Nonetheless, there is a glimmer of hope as several innovative locally-developed drugs are emerging, potentially revolutionizing the fight against these resistant pathogens. One standout is Enmetazobactam, created by Orchid Pharma in Chennai, which has gained approval from the US Food and Drug Administration (FDA). This injectable antibiotic targets the defense mechanisms of bacteria rather than the bacteria itself, cleverly neutralizing enzymes that destroy traditional antibiotics.Dr. Maneesh Paul, a co-inventor of the drug, emphasized its unique design that immobilizes bacterial resistance, thus preserving the effectiveness of existing antibiotics like carbapenems, which are often the last line of defense for critical patients. Clinical trials spanning 19 countries, involving over 1,000 patients, have confirmed its efficacy, marking a significant milestone for Indian pharmaceutical innovation.Another promising antibiotic, Zaynich, is currently undergoing Phase-3 trials by Mumbai-based Wockhardt, which claims it can combat all major superbugs. Preliminary compassionate-use trials on critically ill patients showed a remarkable survival rate, indicating Zaynich’s potential to save lives in dire situations. Alongside it, Wockhardt is also testing Nafithromycin—targeted at a high-resistance bacterial pneumonia—with expectations for commercial launch next year.In the research sector, Bugworks Research, a Bengaluru-based biopharma firm, has embarked on a collaborative project with the Global Antibiotic Research and Development Partnership (GARDP) to formulate a new class of antibiotics, with the initial stages currently underway. However, industry leaders express concern over insufficient innovation and funding for antibiotic development, emphasizing that the financial focus remains disproportionately on treatments for chronic diseases.The growing concern surrounding antimicrobial resistance has prompted a call for change, highlighted by alarming findings from an Indian Council of Medical Research study, which revealed significant rises in resistance for common pathogens. The data indicated that E. coli and Klebsiella pneumoniae are evolving concerningly, with some common antibiotics proving ineffective against them. Dr. Manica Balasegaram from GARDP remarked on the need for continuous innovation in the face of rapidly evolving bacteria. Collaborative efforts are already underway, with GARDP working on a novel antibiotic for gonorrhea and other partners exploring solutions for tough infections like UTIs.However, experts caution against the misuse of new antibiotics, advocating for a shift towards responsible prescribing practices that prioritize narrow-spectrum antibiotics over broad-spectrum ones. The focus on better hygiene, sanitation, and vaccination uptake is equally vital in combating rising drug resistance. A holistic approach involving education, healthcare reforms, and systemic accountability is urgently needed in India's battle against superbugs, lest we face a future where even minor infections could become a dire threat.